NEW YORK, May 29 – HTS Biosystems announced Tuesday plans to establish an office in Yokohama, Japan in its effort to grow its proteomics business in the Asian market.
HTS of Hopkinton, Mass., has appointed Masaaki Sasajima as vice president of Asian Operations and head of HTS Asia.
Sasajima, who previously worked for the life science and diagnostics unit of Mitsubishi Chemical, will be in charge of developing the company’s business in Asia and managing its relationship with Mitsubishi Chemical, which has exclusive rights to distribute HTS’s surface plasmon resonance technology in Japan.
“Mr. Sasajima's longstanding experience in biotechnology and worldwide operations will be crucial as we promote the company and our core technology in Asia,” Greg Freitag, CEO of HTS Biosystems, said in a statement. “Asia represents an important long-term business opportunity and a significant source of revenue.”
Sasajima and Mitsubishi will also collaborate on technological enhancements regarding chip chemistries and advanced chip structures that will improve manufacturability of chips and performance of the company’s Flex Chip Kinetic Analysis System. The company previously said it plans to introduce the Flex Chip, its first product, in the second half of next year. The Flex Chip system uses HTS proprietary technology to enable real-time detection of biomolecular events without reporter labels.
Freitag was not immediately available for comment.
HTS is 73 percent owned by Minnesota-based Quantech and 18 percent owned by Applied Biosystems.